Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination. - sprookjes - yvandenbroek - TriplyDB

Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.

Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.

http://www.wikidata.org/entity/Q34947144

about

Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine The intranasal adjuvant Endocine™ enhances both systemic and mucosal immune responses in aged mice immunized with influenza antigen.

P2860

Q34070683-62C0D742-6578-4D71-92C8-D4D15D57CB36 Q34513477-A0CAB221-56ED-47AF-BC51-93085066371D Q35913758-517015B0-6252-48B6-B835-254B8A908502 Q37061815-29D05F74-11DD-4D3A-AECC-1E19D44BDAF5 Q37679085-1B310A36-F312-46A6-9505-E5C8A2B1B16F

P2860

Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.

http://www.wikidata.org/entity/Q34947144

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@ast

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@en

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@nl

type

label

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@ast

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@en

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@nl

prefLabel

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@ast

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@en

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@nl

P1433

Q34947144-A8F5D4F8-8274-4DA0-B21A-AAB2CB536B93

P1476

Q34947144-FF7D15D2-2664-43FC-925D-DFD8E60106FE

P2093

Q34947144-72FA6068-F9B4-48E5-A91C-37149210696B

Q34947144-79DD6487-A406-4FA1-B222-1C6D554F7775

Q34947144-8DCE5F46-C075-45DB-83CD-E0E30D50B461

Q34947144-E98ABAE1-73D7-4FEA-BE6D-A47F979D8F7D

P2860

Q34947144-01134669-886B-4FEF-A10A-B2188D512348

Q34947144-0F7D6266-566D-4E2F-9456-52F88F8E68B7

Q34947144-14063AF5-566F-4ADC-8896-7B05136DF509

Q34947144-1A30EC57-60C9-4A57-99A1-ACD8F8F3EB30

Q34947144-23202839-25CA-492E-AB6C-6CC8907CB723

Q34947144-28FAACD4-84E1-48B1-8D2B-FEE62DF05C94

Q34947144-2DA87368-ED42-47FA-9BD8-12C05AB1BCE9

Q34947144-317EB3D5-9C0E-4088-B148-CC30059C2EC1

Q34947144-3379E54B-F94A-4DAF-A72E-572D635E9E3E

Q34947144-3F92B9A6-B27F-450D-988A-6A589A3C8863

P304

Q34947144-CBCE73BC-8B56-4A25-B01A-E561A4BD79AA

P31

Q34947144-25C82003-BC70-418B-B95A-AD83F3E1950C

P356

Q34947144-D7A7A598-2C4F-4B39-97AC-08344937DC82

P407

Q34947144-7070EF29-BFA5-4BD4-97B0-FF30D3D3B299

P433

Q34947144-2F3560D6-73C0-4662-9D98-40A716CA1AC2

P478

Q34947144-89E976BE-959A-4FB6-912E-CB17AED2CA7A

P50

Q34947144-3B5DADBD-4AF7-46FF-AD55-B750E5B1E47F

Q34947144-EF569A81-3E70-445C-8530-086CA36373E6

P577

Q34947144-3AB4EA86-F51D-42E7-9008-4D5ED53DD093

P5875

Q34947144-AE9F5F43-D32A-4A53-A052-E8E5ECC45B15

P698

Q34947144-C666AE94-CD18-4F98-ABB4-5E5FC485BFAC

P932

Q34947144-B3726F8D-E198-4E96-B9CA-C1D1CC58AE00

P356

JOURNAL.PONE.0070527

P1433

P1476

Endocine™, N3OA and N3OASq; th ...... o nasal influenza vaccination.

@en

P2093

Andreas Bråve

http://www.w3.org/2001/XMLSchema#string

Britt Akerlind

http://www.w3.org/2001/XMLSchema#string

Tina Falkeborn

http://www.w3.org/2001/XMLSchema#string

Ulf Schröder

http://www.w3.org/2001/XMLSchema#string

P2860

Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses

Highly Conserved Protective Epitopes on Influenza B Viruses

Pandemic versus epidemic influenza mortality: a pattern of changing age distribution

Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance

Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.

Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets

Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain.

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus.

Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants.

P304

e70527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0070527

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255959574

http://www.w3.org/2001/XMLSchema#string

P698

23950951

http://www.w3.org/2001/XMLSchema#string

P932

3738562

http://www.w3.org/2001/XMLSchema#string